China-based contract research organization (CRO) Sangon Biotech has secured RMB 2 billion (USD 290.3 million) in its first financing round, led by GL Capital. Joining the round are CITIC Private Equity, Greenwoods Investment, Huagai Capital, and Guokai Technology Venture Investment. This significant funding will enable Sangon to accelerate human resource recruitment and increase R&D investment for its life science clients, which include universities and pharmaceutical companies.
Sangon Biotech’s Global Ambitions and Service Offerings
Established in Shanghai in 1995, Sangon Biotech aims to expand its operations globally, providing comprehensive research services. The company’s key offerings encompass DNA synthesis, gene sequencing, chemical and biological reagents, molecular biology kits, proteins, antibodies, and laboratory consumables. With this investment, Sangon is poised to enhance its capabilities and meet the growing demands of the life science industry.
Enhancing Research and Development Capabilities
The funding will be instrumental in bolstering Sangon’s R&D efforts, allowing the company to innovate and provide cutting-edge solutions to its clients. This expansion aligns with the growing global need for advanced research services in the life sciences sector.-Fineline Info & Tech
